HS-20117 + HS-20093

HS-20117 + HS-20093 is a combination of two investigational antibody-based therapies developed for the treatment of advanced solid tumors. HS-20117 (also known as PM1080) is a fully human bispecific antibody targeting both EGFR and cMet, designed to inhibit tumor growth by binding to these tumor antigens. It is being evaluated in phase I clinical trials, particularly for advanced solid tumors such as non-small cell lung cancer (NSCLC) with specific EGFR mutations and colorectal cancer (CRC) with RAS/BRAF wild type[2][4]. HS-20093 (also known as GSK5764227) is a B7-H3-targeted antibody-drug conjugate composed of a fully human anti-B7-H3 monoclonal antibody covalently linked to a topoisomerase inhibitor payload. It has shown promising antitumor activity in several tumor types, especially small-cell lung cancer (SCLC), and is under investigation in multiple phase I–III clinical trials for various solid tumors including lung cancer, sarcoma, head and neck cancers[3][5][6][7]. Both drugs are part of Hansoh Pharma’s oncology pipeline; GSK holds global rights outside Greater China for the development and commercialization of HS-20093.